Melissa Stern

Quantitation of physiological and biochemical barriers to siRNA liver delivery via lipid nanoparticle platform.

Marian E. Gindy, J. Hochman, M. Ou, 2014, Molecular pharmaceutics.

A High-Throughput Dose-Response Cellular Thermal Shift Assay for Rapid Screening of Drug Target Engagement in Living Cells, Exemplified Using SMYD3 and IDO1

R. Annan, A. P. Graves, D. Mcnulty, 2018, SLAS discovery : advancing life sciences R & D.

Discovery of Isoxazole Amides as Potent and Selective SMYD3 Inhibitors.

J. Luengo, A. P. Graves, M. Pappalardi, 2019, ACS medicinal chemistry letters.

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers

Xiping Zhang, M. T. McCabe, R. Kruger, 2018, Oncogenesis.

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors

J. Winter, J. Leonard, Juanita Lopez, 2019, Clinical Cancer Research.

Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates.

B. Carr, L. Sepp-Lorenzino, Rob S. Burke, 2014, Journal of controlled release : official journal of the Controlled Release Society.